Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei‐Gardini, Alessandro Cucchetti, Toshifumi Tada et al.|Liver International|2021Cited by 60